Navigation Links
Cynosure Appoints William T. Kelley as Senior Vice President of International Sales
Date:2/25/2009

Laser Industry Executive to Head Company's Network of International Subsidiaries and Distributors

WESTFORD, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the appointment of William T. Kelley as Senior Vice President of International Sales. He will be responsible for the company's direct subsidiaries in four European countries, Japan, China and Korea, and for Cynosure distributors covering an additional 55 countries.

"Bill brings more than 25 years of experience in the medical device industry and a track record of success in growing a global distribution organization," said Michael Davin, Cynosure's President and Chief Executive Officer. "Bill has extensive background in the aesthetic and surgical laser market, and is an ideal choice to help us expand the reach of our aesthetic products around the world."

Since 2004 Kelley was director of international sales at Sciton Inc., a privately held aesthetic device company based in Palo Alto, California, where he was responsible for all business activity outside the United States. Prior to that he served as vice president and general manager for Asclepion-Meditec Inc., the surgical laser division of international optics leader Carl Zeiss AG. As vice president of worldwide sales and marketing for Summit Technology, a maker of ophthalmic excimer laser systems, he supervised the company's direct sales forces in the United States, the United Kingdom and Scandinavia as well as distributors in other regions. From 1985 to 1991 he was general manager of Pfizer Laser Systems, the surgical laser division of Pfizer Corp.

"Cynosure has worked hard to build its base of direct subsidiaries, expanding its overseas distribution network and establishing its brand as a standard of quality in more than 60 countries," Kelley said. "I am excited about the opportunity to guide its international organization and to help execute on Cynosure's strategic plan for financial and operational success."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Safe Harbor

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

    Contact
    Scott Solomon
    Vice President
    Sharon Merrill Associates, Inc.
    617-542-5300
    cyno@investorrelations.com


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008
2. Cynosure to Announce Fourth-quarter and Full-year 2008 Financial Results on February 10
3. Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008
4. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
5. Cynosure to Announce Second-Quarter 2008 Financial Results on July 29
6. Cynosure President and CEO Michael Davin Named Ernst & Young Entrepreneur of the Year(R) 2008 Award Winner in New England
7. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
8. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
9. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
10. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
11. Cynosure Launches Three Aesthetic Products at American Academy of Dermatology 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: